Seminars in Nephrology
Volume 26, Issue 3 , Pages 234-243 , May 2006

Vaptans and the Treatment of Water-Retaining Disorders

  • Friedericke Quittnat
    • ,
  • Peter Gross

      Affiliations

    • P.G. has been an investigator in clinical study protocols of vasopressin antagonists from Wyeth Ayerst (lixivaptan or VPA 985), Münster, Germany; from Astellas (conivaptan or YM 087), Heidelberg, Germany; from Sanofi Recherche (SR 121 463 B), Berlin, Germany; and from Otsuka Pharmaceutical Co. Ltd. (tolvaptan, OPC 41061), Frankfurt, Germany.
    • Corresponding Author InformationAddress reprint requests to Peter Gross, MD, Nephrologie, Medizinische Klinik III, Universitätsklinikum C.G. Carus, Fetscherstrasse 74, D-01307 Dresden, Germany.

References 

  1. Gross P , Pehrisch H , Rascher W , et al.   Pathogenesis of clinical hyponatremia (Observations of vasopressin and fluid intake in 100 hyponatremic medical patients) . Eur J Clin Invest . 1987;17:123–129
  2. Hoorn EJ , Lindemans J , Zietse R . Development of severe hyponatremia in hospitalized patients (Treatment-related risk factors and inadequate management) . Nephrol Dial Transplant . 2006;21:70–76
  3. Musch W , Xhaet O , Hedeshi A , et al.   Fall is a frequent motif of admission in patients with chronic hyponatremia . J Am Soc Nephrol . 2003;14:748A; (abstr)
  4. Renneboog B , Vandemergel X , Manto M , et al.   Is asymptomatic hyponatremia a myth? . J Am Soc Nephrol . 2003;14:746A; (abstr)
  5. Arieff AI . Hyponatremia, convulsions, respiratory arrest, and permanent brain damage after elective surgery in healthy women . N Engl J Med . 1986;314:1529–1534
  6. Robertson GL , Mahr EA , Athar S , et al.   Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma . J Clin Invest . 1973;52:2340–2352
  7. Leaf A , Mamby AR . An antidiuretic mechanism not regulated by extracellular fluid tonicity . J Clin Invest . 1952;31:60–71
  8. Weston RE , Grossman J , Borun ER , et al.   The pathogenesis and treatment of hyponatremia in congestive heart failure . Am J Med . 1958;25:558–572
  9. Gross PA , Anderson RJ . Effects of DDAVP and AVP on sodium and water balance in conscious rat . Am J Physiol . 1982;243:R512–R519
  10. Verbalis JG . An experimental model of syndrome of inappropriate antidiuretic hormone secretion in the rat . Am J Physiol . 1984;247:E540–E553
  11. Anderson RJ , Cadnapaphornchai P , Harbottle J , et al.   Mechanism of effect of thoracic inferior vena cava constriction on renal water excretion . J Clin Invest . 1974;54:1473–1479
  12. Linas SL , Anderson RJ , Guggenheim SJ , et al.   Role of vasopressin in impaired water excretion in conscious rats with experimental cirrhosis . Kidney Int . 1981;20:173–180
  13. Yaron M , Bennett CM . Mechanism of impaired water excretion in acute right ventricular failure in conscious dogs . Circ Res . 1978;42:801–805
  14. Mandell IN , De Fronzo RA , Robertson GL , et al.   Role of plasma arginine vasopressin in the impaired water diuresis of isolated glucocorticoid deficiency in the rat . Kidney Int . 1980;17:186–195
  15. Boykin J , De Torrente A , Robertson GL , et al.   Persistent plasma vasopressin levels in the hypoosmolar state associated with mineralocorticoid deficiency . Miner Electrolyte Metab . 1979;2:310–315
  16. Flear CTG , Hilton P . Hyponatremia and severity and outcome of myocardial infarction . Br Med J . 1979;1:1242–1246
  17. Bichet D , Szatalowicz V , Chaimovitz C , et al.   Role of vasopressin in abnormal water excretion in cirrhotic patients . Ann Intern Med . 1982;96:413–417
  18. Usberti M , Federico S , Meccariello S , et al.   Role of plasma vasopressin in the impairment of water excretion in nephrotic syndrome . Kidney Int . 1984;25:422–429
  19. Skowsky WR , Kikuchi TA . The role of vasopressin in the impaired water excretion of myxedema . Am J Med . 1978;64:613–621
  20. Schrier RW , Berl T . Nonosmolar factors affecting renal water excretion . N Engl J Med . 1975;292:81–87 141–
  21. Rossi NF . The mechanisms of K-opioid agonist-induced water diuresis (Central vs. peripheral actions) . In:  Saito T ,  Kurokawa K ,  Yoshida S editor. Neurohypophysis, Recent Progress of Vasopressin and Oxytocin Research . Amsterdam: Elsevier; 1995;p. 289–299
  22. Manning M , Sawyer WH . Development of selective agonists and antagonists of vasopressin and oxytocin . In:  Schrier RW editors. Vasopressin . New York: Raven Press; 1985;p. 131–144
  23. Burnier M , Waeber B , Nussberger J , et al.   Cardiovascular effects of vascular antagonists (V1) to the action of vasopressin in health and diseases . In:  Cowley AW ,  Liard JF ,  Ausiello DA editor. Vasopressin, Cellular and Integrative Functions . New York: Raven Press; 1988;p. 473–480
  24. Oksche A , Leder G , Valet S , et al.   Variant amino acids in the extracellular loops of murine and human vasopressin V2 receptors account for differences in cell surface expression and ligand affinity . Mol Endocrinol . 2002;16:799–813
  25. Adrogué HJ , Madias NE . Hyponatremia . N Engl J Med . 2000;342:1581–1589
  26. Singer I , Rotenberg D . Mechanisms of lithium action . N Engl J Med . 1973;289:254–260
  27. Decaux G , Brimioulle S , Genette F , et al.   Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by urea . Am J Med . 1980;69:99–106
  28. Hantman D , Rossier B , Zohlman R , et al.   Rapid correction of hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone. An alternative treatment to hypertonic saline . Ann Intern Med . 1973;78:870–876
  29. Jard S . Mechanisms of action of vasopressin and vasopressin antagonists . Kidney Int . 1988;34:S38–S42
  30. Michell RH , Kirk CJ , Billah MM . Hormonal stimulation of phophatidylinositol breakdown, with particular reference to the hepatic effects of vasopressin . Biochem Soc Trans . 1979;7:861–865
  31. Thibonnier M , Colos P , Thibonnier A , et al.   The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists . Annu Rev Pharmacol Toxicol . 2001;41:175–202
  32. Hayashi M , Sasaki S , Tsuganezawa H , et al.   Expression and distribution of aquaporin of collecting duct are regulated by vasopressin V2 receptor in rat kidney . J Clin Invest . 1994;94:1778–1783
  33. Innamorati G , Sadeghi H , Eberle AN , et al.   Phosphorylation of the V2 vasopressin receptor . J Biol Chem . 1997;272:2486–2492
  34. Kojro E , Fahrenholz F . Ligand-induced cleavage of the V2 vasopressin receptor by a plasma membrane metalloproteinase . J Biol Chem . 1995;270:6476–6481
  35. Sadeghi HM , Innamorati G , Birnbaumer M . Functional properties of mutant V 2 receptors . In:  Saito T ,  Kurokawa K ,  Yoshida S editor. Neurhypophysis, Recent Progress of Vasopressin and Oxytocin Research . Amsterdam: Elsevier; 1995;p. 445–451
  36. Fujiwara TM , Bichet DG . Molecular biology of hereditary diabetes insipidus . J Am Soc Nephrol . 2005;16:2836–2846
  37. Yamamura Y , Ogawa H , Yamashita H , et al.   Characterization of a novel aquaretic agent, OPC 31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist . Br J Pharmacol . 1992;105:787–791
  38. Fujisawa G , Ishikawa S-E , Tsuboi Y , et al.   Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats . Kidney Int . 1993;44:19–23
  39. Saito T , Fujita N , Fujisawa G , et al.   Correction of water retention due to vasopressin excess by nonpeptide vasopressin antagonists . In:  Saito T ,  Kurokawa K ,  Yoshida S editor. Neurohypophysis (Recent Progress of Vasopressin and Oxytocin Research) . Amsterdam: Elsevier; 1995;p. 635–642
  40. Ohnishi A , Orita Y , Okahara R , et al.   Potent aquaretic agent . J Clin Invest . 1993;92:2653–2659
  41. Chan PS , Coupet J , Park HC , et al.   VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist . In:  Zingg HH ,  Bourque CW ,  Bichet DG editor. Vasopressin and Oxytocin; Molecular, Cellular and Clinical Advances . New York: Raven Press; 1998;p. 439–443
  42. Gross P , Decaux G , Gerbes AL , et al.   Double blind, placebo-controlled study of the activity and tolerance of two doses of VPA-985 in patients with hyponatremia . J Am Soc Nephrol . 1999;10:121A; (abstr)
  43. Gerbes AL , Gülberg V , Ginès P , et al.   Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist (a randomized double-blind multicenter trial) . Gastroenterology . 2003;124:933–939
  44. Tahara A , Tomura Y , Wada K , et al.   Pharmacological profile of YM 087, a novel potent nonpeptide vasopressin V1a and V2 receptor antagonist, in vitro and in vivo . J Pharmacol Exp Ther . 1997;282:301–306
  45. Risvanis J , Naitoh M , Johnston CI , et al.   In vivo and in vitro characterisation of a nonpeptide vasopressin V1a and V2 receptor antagonist (YM 087) in the rat . Eur J Pharmacol . 1999;381:23–30
  46. Burnier M , Fricker AF , Hayoz D , et al.   Pharmacokinetic and pharmacodynamic effects of YM 087, a combined V1/V2 vasopressin receptor antagonist in normal subjects . Eur J Clin Pharmacol . 1997;55:633–637
  47. Ghali JK , Verbalis JG , Gross P , et al.   Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure . J Am Soc Nephrol . 2005;16:43A; (abstr)
  48. Serradeil-Le Gal C , Lacour C , Valette G , et al.   Characterisation of SR 121 463 A, a highly potent and selective, orally active vasopressin V2 receptor antagonist . J Clin Invest . 1996;98:2729–2738
  49. Soupart A , Gross P , Legros JJ , et al.   Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion in with SR 121 463 B, an orally active, nonpeptide, vasopressin V-2 receptor antagonist . J Am Soc Nephrol . 2004;15:563A; (abstr)
  50. Yamamura Y , Nakamura S , Itoh S , et al.   OPC-41061, a highly potent human vasopressin V2-receptor antagonist (Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats) . J Pharmacol Exp Ther . 1998;287:860–867
  51. Hirano T , Yamamura Y , Nakamura S , et al.   Effects of the V2-receptor antagonist OPC 41061 and the loop diuretic furosemide alone and in combination in rats . J Pharmacol Exp Ther . 2000;292:288–294
  52. Monillac B , Chini B , Balestre MN , et al.   The binding site of nonpeptide vasopressin V1a receptor. Evidence for a major localization within transmembrane regions . J Biol Chem . 1995;270:25771–25777
  53. Esnouf RM . Further additions to MolScript version 1.4, including reading and contouring of electron-density maps . Acta Crystallogr D Biol Crytallogr . 1999;55:938–940
  54. Merritt EA , Murphy ME . Raster3D version 2.0. A program for photorealistic molecular graphics . Acta Crystallogr D Biol Crytallogr . 1994;50:869–873
  55. Macion-Dazard R , Callahan N , Xu Z , et al.   Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor . J Pharmacol Exp Ther . 2006;316:564–571

PII: S0270-9295(06)00014-3

doi: 10.1016/j.semnephrol.2006.02.003

Seminars in Nephrology
Volume 26, Issue 3 , Pages 234-243 , May 2006

Article Tools

* Image Usage & Resolution